http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences
-
Krystal Biotech's (KRYS) Jeune Aesthetics Reports Positive Clinical Phase 1 Efficacy Results for KB301
-
Jeune Aesthetics Announces Positive Clinical Phase 1 (PEARL-1 Study) Efficacy Results for KB301, an Investigational Gene-based Treatment Designed to Address the Underlying Biology of Aging Skin
-
Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
-
Krystal Biotech (KRYS) Settles with PeriphaGen
-
Krystal Biotech Announces Settlement with PeriphaGen, Inc.
-
Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational Progress
-
Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference
-
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
-
Jeune Aesthetics Leadership to Present at Octane’s 3rd Annual Aesthetics Tech Summit
-
Pre-Open Stock Movers 11/29: (KRYS) (ADGI) (TWTR) Higher; (MRK) (UPS) Lower (more...)
-
Krystal Biotech (KRYS) Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa
-
Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa
-
Jeune Aesthetics to Present Pre-clinical Data Highlighting the Potential of KB303 in Elastin Production at the ASDS 2021 Virtual Meeting
-
Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress
-
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
